AgenT develops the first blood diagnosis to detect Alzheimer's disease from the asymptomatic stage.
AgenT has raised $2.7M in total funding. The most recent round was Seed. The last funding was announced in July 2021.
AgenT's investors include Creative Destruction Lab, IncubAlliance Paris-Saclay, Bernard Majoie.
AgenT is headquartered in Paris, France.
AgenT develops the first blood diagnosis to detect Alzheimer's disease from the asymptomatic stage.
AgenT is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AgenT — Funding & Investors." VCBacked, July 1, 2021, https://www.vcbacked.co/company/agent. Accessed September 30, 2026.
VCBacked. (2021). AgenT — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/agent
{{cite web |title=AgenT — Funding & Investors |url=https://www.vcbacked.co/company/agent |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated